Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HYR-PB21 (Hengrui Therapeutics)
- Development stage
- Unknown
- Lead developer
- Hefei Cosource Pharmaceutical
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Parenteral
01
Overview
HYR-PB21 is a long-acting, sustained-release liposomal formulation of the local anesthetic bupivacaine, developed by Jiangsu Hengrui Pharmaceuticals. It is specifically designed for regional analgesia, such as paravertebral nerve blocks, to provide prolonged pain relief. Bupivacaine, the active ingredient, functions by blocking voltage-gated sodium channels on the internal surface of nerve cell membranes, thereby preventing the generation and conduction of nerve impulses. This formulation aims to extend the duration of action compared to standard bupivacaine injections, making it suitable for managing chronic pain conditions like postherpetic neuralgia (PHN) and acute postoperative pain. HYR-PB21 is currently being evaluated in Phase I clinical trials for its efficacy, safety, and pharmacokinetic profile in patients with PHN.
- Other names
- bupivacaine liposomebupivacaine multivesicular liposomebupivacaine liposome injectable suspension
02
Targets
SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN4A (Voltage-gated sodium channel protein type 4 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)SCN8A (NaV1.6)SCN9A (Sodium channel protein type 9 subunit alpha)
Beyond the preview
Go deeper on HYR-PB21 (Hengrui Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HYR-PB21 (Hengrui Therapeutics).